It does make you wonder how this gets press and Brilacidin doesn’t seem to. Even though nothing has come close pre-clinical to it. Waiting on human trials and/ or partnership validation. Drugs involving antibodies don’t seem to be working all that great if at all. Also Regeneron’s cocktail poses a real issue with mass production, and mutations.
News 
Market Data 
Discover 
AI
